MAPS / Lykos Therapeutics

Rule Changes

As of May 2026: Pursuing revised MDMA therapy application after 2024 FDA rejection

For 55 years, the federal government classified psilocybin, MDMA, LSD, and ibogaine as Schedule I substances. On April 18, 2026, President Trump signed an executive order 'Accelerating Medical Treatments for Serious Mental Illness' directing the FDA to expedite clinical trials of those substances for PTSD in veterans.

Updated May 31